Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind study of CXA-201 versus levofloxacin in complicated urinary tract infection including pyelonephritis
2010-023452-87Phase 3Completed
- Sponsor
- Cubist Pharmaceuticals, Inc.
- Start
- Feb 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in complicated urinary tract infection (cUTI) and pyelonephritis comparing CXA-201 intravenous arm with Levofloxacin intravenous arm (2 arms). Primary endpoint: Primary efficacy endpoint. Started Feb 2011; status: completed.
02
Drugs
ceftolozane + tazobactamlevofloxacin
03
Conditions
complicated urinary tract infection (cUTI)pyelonephritis
Beyond the preview
Go deeper on 2010-023452-87.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023452-87.